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Abstract
Background & Aims—African Americans (AA) are an admixed population of West African
(WA) and European ancestry (EA). Crohn's disease (CD) susceptibility genes have not been
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established. We therefore evaluated the contribution of European admixture and major established
risk genes to AA CD.
Methods—Ninety-seven admixture informative markers were genotyped for ancestry estimates
using STRUCTURE. 354 AA CD cases and 354 ethnicity-matched controls were genotyped for
total 21 SNPs in ATG16L1, NOD2, IBD5, IL23R and IRGM by TaqMan or direct sequencing.
Association was evaluated by logistic regression, adjusted for ancestry.
Results—Mean EA was similar among the CD cases and controls (20.9% and 20.4, respectively,
p=0.58). No significant admixture differences were observed among cases (211 to 227) stratified
by phenotypic sub-classifications including onset, surgery, site, and behavior. CD was associated
with NOD2 carrier (6.93% CD, 2.15% Controls, p = 0.007), ATG16L1 Thr300Ala (36.1% CD,
29.3% Controls, p=0.003), SLC22A4 and SLC22A5 (IBD5 locus) functional SNPs (L503F
[10.6% CD, 7.6% Controls, p=0.05] and g-207c [41.3% CD, 35.7% Controls, p=0.03],
respectively) and IL23R rs2201841 (18.2% CD, 13.8% Controls, p=0.03), but not IRGM variants
nor three African ancestral NOD2 nonsynonymous variants. IBD5 risk was recessive. An all-
minor allele IBD5 haplotype from EA was associated (p=0.05), whereas a more common
haplotype isolating g-207c was not.
Conclusions—Specific functional gene variations significantly contribute to AA CD risk.
Established NOD2, SLC22A4-A5, and ATG16L1 variants show increased CD risk, with IBD5 in
recessive. Although CD is more common in whites, European admixture is similar among AA
cases and controls.
Keywords
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Introduction
Historically, Crohn's disease (CD) incidence has been substantially lower in African
Americans (AA) than white American populations. Some recent studies still show this,
whereas two studies found hospitalization rates greatest among AA females.1, 2 AA CD
prevalence in the population-based Kaiser Health Maintenance Organization study was two-
thirds that of whites.2 Compared to most white populations, where ulcerative colitis (UC)
occurs slightly more frequently than CD, in AA's CD incidence in children was observed
1.6-fold greater than UC suggesting potential etiological differences.3 CD phenotype
features may also be different among races: we found AA's had significantly greater odds of
colon-only and perianal disease, had lower odds of penetrating disease, and (for both CD
and UC) greater odds of uveitis and sacroiliitis (2.1, 1.6, 0.52, 3.7 and 5.8-fold
respectively).4 CD risk to AA siblings was much greater than population prevalence (2.5%
vs. 45/100,000), suggesting that like white CD, AA CD likely has important genetic
influences.4
The AA genome is an admixture of West African and European ancestry. When a phenotype
is more common in one ancestral population compared to another, in an admixed population,
the degree of genetic admixture in individuals with the phenotype often corresponds. For
example, average BMI is greater in AA's than white Americans; correspondingly, BMI is
inversely associated with degree of European ancestry in AA's.5 With CD more prevalent in
whites than AA's, it is important to determine if overall CD risk arises from a relative
increase in European admixture. It is also of interest to investigate whether phenotypic
features more or less common in whites will correlate with the degree of European
admixture.
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Few studies have evaluated the influence of established CD molecular genetic risk factors in
AA's. Nucleotide-binding oligomerization domain containing-2 (NOD2) mutations
Arg702Trp, Gly908Arg and Leu1007fsinsC, the strongest, common CD risk factor in
whites, was first evaluated in 58 AA children with CD and 124 healthy controls (HC's) from
Wisconsin, but showed no association (carriers 3.8% CD vs. 4.3% HC's).6 We evaluated
NOD2 in our initially recruited Mid-Atlantic (now Multicenter) African American IBD
study (MAAIS – a sub-study of the NIDDK IBD Genetics Consortium [IBDGC]) of 183 CD
and 143 HC's and found increased risk (8.2% vs. 2.1%, respectively, P=0.03).7 Given these
discrepant findings, it is important that NOD2 AA risk be more substantiated. The IBD5
locus genes solute carrier family 22, member 4 and member 5 (SLC22A4 and SLC22A5)
were the second genes having functional variations (Leu503Phe and g-207c, respectively)
established as CD genetic risk factors. 8, 9 Whether both genes are required for CD risk and
whether risk lies within variations that influence other proximal genes has not been
discerned, primarily because of strong linkage disequilibrium (LD) within a single,
common, minor allele haplotype found across a 600 kb region in whites.8 The first genome
wide association study (GWAS) in whites established association for the interleukin (IL) 23
receptor gene, IL23R, the receptor product a key regulator of chronic inflammation in CD.10
Multiple IL23R single nucleotide polymorphisms (SNPs) have shown independent CD
association with a poorly conserved albeit uncommon protective variant, Arg381Gln
showing a greater than 3-fold protective effect.10 Autophagy 16 like-1 (ATG16L1) was the
next CD gene established by GWAS; a Thr300Ala resulted in 1.5-fold risk.11, 12 300Ala
reduces autophagasome elimination of bacteria13 further substantiating the concept,
established with NOD2, that defective innate immunity results in CD risk. The Wellcome
Trust GWAS identified variants in immunity-related GTPase family, M (IRGM ) that result
in 1.4-fold CD risk. IRGM encodes a GTP-binding protein that induces autophagy likewise
important to elimination of bacteria, including Mycobacterium tuberculosis.14, 15 IRGM
association may be due to a 20 kb copy number variation (CNV) that influences gene
expression16, 17 and/or a synonymous exon variant (rs10065172 encoding c.313C>T) that
alters miRNA binding of miR-196 to IRGM resulting in loss of IRGM regulation in
inflamed intestinal tissue.18 Of the established CD loci, NOD2, ATG16L1, SLC22A4-A5,
IL23R and IRGM are among the highest risk CD genes (risk ≥ 1.4-fold) where functional
variations have been identified and studied.
In view of the genetic heterogeneity of CD, the unique features of AA genetic ancestry and
CD phenotype features, we performed a study to characterize the overall contributions of
WA and European admixture to AA CD risk and to determine the genetic influences of the
most well established, higher risk CD genes having characterized, functional
polymorphisms.
Methods
Patient Populations (summarized in Supplementary Table 1)
Primary dataset—The study population included unrelated individuals, self-identified as
non-Hispanic AA with a history of confirmed CD, recruited from 2003 to 2007 by the
MAAIS. Similarly, unrelated, self-identified non-Hispanic AA's with no personal or family
history of inflammatory bowel disease (IBD) and no history of chronic diarrhea,
unexplained abdominal pain, rectal bleeding or irritable bowel syndrome were recruited as
non-IBD, ethnically matched HC's. MAAIS recruitment was coordinated at the Johns
Hopkins Genetics Research Center (GRC) of the IBDGC with satellite recruitment at
Howard University, University of Florida, University of North Carolina, University of
Pennsylvania, and the Washington Hospital Center. Twenty-six AA cases, all patients at
Johns Hopkins Hospital, and 13 AA healthy spouse controls were also included.
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IBD family history was defined as IBD in first- or second-degree relatives. Smoking was an
average of at least 1 cigarette daily for at least 3 months prior to diagnosis. CD diagnosis
was confirmed by medical records review per the IBDGC standards in an operations
manual.19
Secondary dataset—This dataset was derived primarily from DNA samples of 66 adults
recruited at the University of Chicago and 59 children recruited at the Medical College of
Wisconsin with confirmed CD.6, 20 DNAs from 12 AA children with confirmed CD were
also received from a Duke University IBD study.21 Lastly, 43 samples were obtained from
non-Hispanic, AA (or African-Canadian) individuals recruited by IBDGC GRC's at
University of Montreal, University of Pittsburgh, University of Toronto and Yale
University. These DNA's were purified from individuals with confirmed diagnoses of CD
(n=14), UC (n=19), indeterminate colitis (n=3) and from 7 controls.4 Additional HC's were
from 152 AA's, without known asthma, common rheumatologic diseases or UC, recruited by
the Baltimore Asthma Severity Study. 22
Phenotyping
Phenotype features for the primary dataset was determined using a previously validated
protocol, largely in accordance with the Montreal classification.19, 23 Age at diagnosis was
by chart review or if necessary, patient questionnaire. Disease location (maximal extent) was
classified as L1 (ileum involvement only), L2 (colonic involvement only), or L3
(ileocolonic). L4 (esophageal, gastric, duodenal or jejunal) involvement was determined
independently of L1-L3. Disease behavior (B1-B3) was per the Montreal classification.24
History of surgery was confirmed bowel resection or diversion for treatment of CD or
complications. Extra-intestinal disease was determined as previously reported.4
Genotyping
Ancestry Estimation—Ninety-six well DNA plates containing case and control samples
on each plate, unique positioned water controls, 13 blinded duplicates and 5 blinded white
controls were genotyped using 97 ancestry informative markers (AIM's) by the Kittles
laboratory as described.25, 26
Candidate SNPs—Samples from cases and HC's were plated together, and laboratory
personnel were blinded to disease status. Seventeen SNPs were genotyped using Applied
Biosystem's Taqman 5'-exonuclease assays, with alleles determined on an Applied
Biosystems 7900HT Fast Real-Time PCR System analyzer. Three NOD2 SNPs (R702W,
R708H, R790Q) were determined by direct sequencing of PCR products, and P268S was
genotyped by PCR-RFLP.
Statistical analysis
Admixture determination—AIM genotypes from cases, HC's, duplicates and unknown
samples were compared with the same AIM genotypes from DNA samples of WA's and
Europeans. The data was used to determine fraction of European vs. WA ancestry using the
program STRUCTURE 2.3 as described.26, 27 Each individual's estimated percentage of WA
and European ancestry was coded as a continuous variable. Individuals with more than 85%
European ancestry were excluded from analyses.5 Power to observe a significant difference
of European ancestry between AA cases and matched controls was calculated by assuming
European ancestry differences from 1% to 5%, and alpha level 0.05, using SAS 9.1 package
program (SAS Institute, Cary, NC).
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Phenotype and demographic comparisons with admixture—Within cases,
associations between WA ancestry and CD disease behaviors, sites of involvement, extra-
intestinal disease, IBD family history and age at diagnosis were assessed by T-test,
ANOVA, and logistic regression.
Genotype association analyses—Analyses were performed by SAS 9.1/Genetics
package program (SAS Institute, Cary, NC). Two sample t-tests were used for continuous
variables. Nominal data were analyzed using the χ2 test. A two-tailed P <0.05 was
considered significant. Logistic regression model was used to calculate genetic association
after adjusting calculated WA ancestry. Population attributable risk (PAR) was calculated as
reported previously.28 For haplotype analysis, pairwise LD was calculated by PROC
ALLELE using SAS 9.1. Association between each haplotype and risk of CD was estimated
by regression substitution, a function implemented in the R program HaploStat.29 We
applied Benjamini and Hochberg false discovery rate (FDR) to correct for multiple testing.30
Results
West African/European admixture analysis among MAAIS participants
We genotyped 227 confirmed CD cases and 201 HC's from the primary dataset. Two AIMs
were dropped because genotyping rates less than 20%. For the remaining 95 AIM's,
genotyping call rate was between 96.3% and 100%. Among the 13 blinded duplicate control
paired samples, one DNA failed to genotype completely. For the remaining 12 pairs of 24
samples, genotyping call rate was 97%, and 99.6% of those genotypes called in both pairs
were identical. For the five blinded white control subjects WA ancestry ranged from 2.1% to
5.0%. Among all MAAIS study subjects, calculated WA ancestry ranged from 28.6% to
97.5%, excluding one self-identified AA HC with 2.2% WA ancestry (i.e. 97.8% European
ancestry). We had 29%, 56%, and 80% power to identify a significant difference in
admixture of 2%, 3% and 4% based on a sample of 200 pairs of case and control.
Characteristics of the 227 MAAIS CD and 200 matched control patients with satisfactory
AIM's genotyping and WA ancestry greater than 15% are presented in Table 1. CD Study
subjects showed a non-significant trend for younger age at study entry and female gender.
There was no significant difference in tobacco use. Mean age at CD diagnosis was 26.8
(Standard Deviation [SD] 12.9) years and IBD family history 15.9%. Similar to our initial
report, colon-only disease was relatively frequent (30.8%).4 Disease behavior was
inflammatory (B1) in 40.5%, stricturing (B2) in 29.5%, and penetrating (B3) in 22.9%, with
average length of observation between diagnosis and phenotype evaluation 10.8 years (SD
8.6 years).
Admixture and CD disease and phenotypes
There were no differences in overall mean estimated WA ancestry: 79.6% (SD 11.6%) in
cases and 79.8% (SD11.9%) in HC's (p=0.86). WA ancestry was not different by disease
site: L1 80% (SD 12.4%), L2 80% (SD 10.1%), and L3 79% (SD 12.4%), p=0.13, and there
was no difference in WA ancestry in ileal involvement (L1 and L3) vs. colon-only disease
(L2) (p=0.55). WA ancestry did not differ by disease behavior: B1 81.2% (SD11.1%), B2
77.7% (SD12.6%) and B3 78.8% (SD 11.8%), p=0.17. There was a trend towards greater
WA ancestry among persons with inflammatory disease (B1) relative to complicated disease
(B2 or B3), WA ancestry 78.1% (SD 12.2) p=0.07. However, after excluding B1 with short
length of disease (< 6 years), association evidence weakened, but most directly because of
smaller sample size as WA ancestry percentage remained the same: WA ancestry B1≥6
years of disease 81.1% (SD 11.4) vs. B2 or B3 78.1% (SD 12.2), p=0.11. Mean WA
ancestry did not differ by perianal disease (present 79.9%, absent 79.7%, p=0.7), by extra-
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intestinal disease (present 80.8%, absent 79%; p=0.3), history of CD intestinal surgery (80%
surgery, 79.3% no surgery; p=0.7), IBD family history (present 79%; absent 79.4%; p=0.9),
or younger age at diagnosis (< age 40 at diagnosis 79.4%, ≥ age 40 at diagnosis 80.9%;
p=0.5). Plots of cumulative proportion of WA ancestry for CD vs. HC's, B1 vs. B2 or B3
behaviors, and L1 or L3 vs. L2 sites are shown in Figure 1.
West African/European ancestry among non-MAAIS study subjects (secondary dataset)
Mean WA ancestry was 78 to 80% for each subset of study subjects with the exception of
the 27 IBD (10 CD) African Canadian cases and controls (n=4) from the Toronto and
Montreal GRCs (mean WA ancestry 90%, consistent with the major origin of African
Canadians from the Caribbean), and therefore these subjects were excluded for further
genotyping. One study subject from University of Chicago, Medical College of Wisconsin
and BASS recruitments each had more than 85% European ancestry and thus excluded from
further analysis. Of the remaining study subjects, mean WA ancestry was 77.9% for the
cases and 79.2% for controls (p=0.41). SNP genotyping quality using DNA's from ten cases
was poor and were excluded from further analysis. This left a total of 127 CD cases and 154
HC's in the secondary cohort for further analysis (Supplementary Table 1). For the
combined primary and secondary datasets of 354 AA CD cases and 354 controls, mean EA
remained highly similar (20.9% and 20.4%, p=0.58 respectively). We had 47%, 80% and
96% power to identify a significant difference in admixture of 2%, 3% and 4%, respectively,
for this sample size.
Genotypic association studies
Genotype call rates were 97% or greater in both datasets, with the exception of the NOD2
SNPs genotyped by direct sequencing (95% call rate). Among HC's, Hardy-Weinberg
Equilibrium (HWE) was ≥ 0.07 for all SNPs except NOD2 R790Q (HWE 0.04)
(Supplementary Table 2). Since there was no significant heterogeneity for any genotyped
SNPs between primary and secondary datasets (Supplementary Table 3), to maximize power
we analyzed genetic association for both datasets combined. (However, because we
recruited cases and controls uniformly in the primary data set, we made their genotyping
results available [Supplementary Table 4]).
NOD2
In the combined dataset (Table 2), presence of any NOD2 mutation (all simple
heterozygotes) was significantly associated with CD (p= 0.007; FDR adjusted p= 0.02).
NOD2 carriage rate was 7.1% CD, 2.2% HC's with OR 3.28 (95%CI: 1.39 – 7.74). For the
individual NOD2 risk mutations, only Leu1007fsinsC was significantly associated with CD
(OR 8.08, 95%CI: 1.01-64.8, p=0.02; adjusted p= 0.04). Pro268Ser (“SNP5”), a common
variant from European admixture, was significantly more frequent among cases (7.4% CD,
4.4% HCs, p=0.02). Using this marker to adjust for local (NOD2 region) admixture in AA's,
we still observed significant risk for the three NOD2 mutations (NOD2 carrier OR after
adjusting SNP5 3.15, 95%CI: 1.16 – 8.56, p=0.01). We also observed that the three NOD2
mutations were more common among individuals with overall lower WA ancestry (76%
WA in NOD2 carriers vs. 79.9% WA in NOD2 non-carriers, p=0.07), although not meeting
criteria of statistical significance.
We sequenced the entire NOD2 coding exons and intron-exon boundaries in 31 AA CD
cases and observed only three additional non-synonymous SNPs (in exon 4) that are
uncommon or non-existent in Europeans (Supplementary Table 2): Arg708His, Ala725Gly
and Arg790Gln. Since these 3 SNPs were proximal to Arg702Trp, and Arg702Trp
genotyped poorly by TaqMan, we genotyped exon 4 SNPs by direct sequencing. However,
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we did not find association evidence for any of these three apparently African ancestral
SNPs (Table 2).
ATG16L1
In AA's, unlike Europeans, the variant G allele that encodes the300Ala CD risk residue, is
the less common allele. Its frequency was 36.1% in CD compared with 29.3% in controls
(p=0.003, adjusted p= 0.02). Analysis of genotypic relative risks showed that CD risk was
significantly increased in both Thr/Ala heterozygotes (OR 1.49, 95%CI: 1.09-2.04, p=0.01)
as well as Ala/Ala homozygotes (OR 1.86, 95%CI: 1.11-3.11, p=0.02) (Table 2).
IBD5
We genotyped five SNPs, which included functional variants Leu503Phe in SLC22A4 and
g-207c promoter variant in SLC22A5, and three marker SNPs more centromeric on the
IBD5 risk haplotype.31 Allelic association was found for Leu503Phe 10.5% CD, 7.6% HC,
p=0.05 and g-207c 41.3% CD, 35.7% HC, p=0.03, with only g-207c marginally significant
after correction for multiple testing (adjusted p=0.06; Table 2). Interestingly, genotypic
analysis showed significant CD risk for all IBD5 SNPs tested for homozygote but not
heterozygote genotypes (Table 2). All five IBD5 SNPs remained significantly associated
with CD for recessive mode of inheritance after FDR correction for multiple testing:
SLC22A4 L503F (adjusted p=0.05), SLC22A5 g-207c (adjusted p = 0.02), IGR2230
(adjusted p=0.03), IGR2198 (adjusted p=0.02), IGR2096 (adjusted p=0.02).
IL23R
Analysis of five genotyped SNPs in IL23R suggested association only for variant alleles in
intron7 SNP rs2201841 OR 1.39 (95%CI: 1.04-1.95, p=0.03, adjusted p=0.06). (Table 2).
Only 4.0% of cases and 5.1% of HC's carried the 381Gln protective variant (p=0.61).
IRGM
Analysis of variant allele frequency and genotypic relative risks for three IRGM SNPs, that
included rs13361189 (in tight LD with the 20kb CNV) and rs10065172 (miRNA binding
variant), showed no associations with CD (Table 2).
Haplotype and Diplotype Analysis
Strong LD was observed between IBD5 variants but less between IL23R variants (Pairwise
D′ values >0.65, r2 value > 0.1; D′ values > 0.02, r2 value > 0.004, respectively). When the
most common IBD5 haplotype, consisting of the five major alleles CGGCG is considered as
reference, no association was observed for the second most common haplotype, consisting
of four major alleles and the SLC22A5 – g207c minor allele (CCGCG; 20.6% CD, 19.2%
HC, p=0.24, Table 3). Similar to that observed in whites28, significant risk was observed for
the all-minor-allele haplotype TCAGT relative to the reference haplotype (9.8% CD, 7.1%
HC, p=0.05). Diplotype association analysis found the only significant association was for
individuals carrying homozygote variants in all five SNPs (TCAGT/TCAGT, OR 8.14,
P=0.03) relative to the wild type diplotype (CGGCG/CGGCG), further supporting the
recessive risk of IBD5 (Supplementary Table 5). For 5-marker haplotype of IL23R,
compared to the most common association haplotype TCGAT, there were two haplotypes
suggesting association with CD (CAGGT P = 0.05, CCGAG P = 0.06, Table 3).
Discussion
NOD2, SLC22A4, SLC22A5, IL23R, ATG16L1 and IRGM are among the most highly
investigated CD risk genes in white populations. This study, the first to evaluate in AA's
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SLC22A4 and SLC22A5, IL23R, ATG16L1, and IRGM and, with more than double the
study population and adjustment for ancestral admixture, to re-evaluate NOD2, found
significant association evidence for established risk alleles for all loci but IRGM. All studies
in white populations have found NOD2 mutations more frequent among CD cases than
controls, with a meta-analysis of 29 studies finding overall NOD2 carrier risk of 3.2.32
However, NOD2 mutations are rare or absent among non-white populations, the three
NOD2 mutations assumed to have arisen in European ancestral populations or by
admixture.33, 34 Our expanded study showed robust association evidence for carriage of any
NOD2 mutation (OR 3.28, p=0.007; FDR adjusted p=0.02), with risk similar to whites,32
and significant association remained even after adjustment for individual admixture.
However, because of lower frequency of mutations in AA's, the estimated AA PAR was
only 4.6 % vs. 22 % in whites.32 We also screened for and genotyped non-synonymous
SNPs common in AA's, to determine if any African ancestral NOD2 mutations contribute to
CD risk, but found no association. Our study showed that in the AA population as in whites,
common NOD2 risk only arises from the 3 major European ancestral loss of function
mutations and for disease prediction purposes only these need to be genotyped. In white
populations, NOD2 mutation homozygotes result in approximately 20-fold CD risk and are
especially predictive of ileal involvement and complicated disease course.35 Indeed, NOD2
is now widely commercially available for these uses. However, we did not observe any
NOD2 homozygotes in our AA CD study population (as opposed to 12% in a study of white
CD patients from Baltimore, Chicago and Pittsburgh IBD centers),35 and with only 0.01% of
the AA population predicted to be NOD2 homozygotes (as opposed to 0.5% homozygote
rate found among combined white controls),36 NOD2's clinical utility in AA's should be
specifically assessed prior to its routine use in this population.
Prior to GWAS, the IBD5 risk haplotype was the only other established genetic risk factor,
with functional variants in SLC22A4 and SLC22A5 as the leading candidate risk variants,
with risk present for both heterozygote and homozygote carriers, although numerous studies
(including a recent meta-analysis) observed a gene-dosage effect, as did the original IBD5
discovery.8, 37 We observed significant association only for homozygote carriers, maximal
for Leu503Phe with point OR estimates of 8.4, far greater than meta-analysis point OR
observed in whites. In contrast to studies in whites, frequency of heterozygotes among AA's
for four IBD5 SNPs were actually lower among cases relative to controls, and for
Leu503Phe heterozygotes had only a slight and non-significant increased presence relative
to wild types (p=0.39).
The SLC22A5 –g207c functional variant, is frequently found in AA's on a haplotype
isolated from the other IBD5 minor alleles variants including the SLC22A4 Leu507Phe
functional variant, However, SLC22A5 showed no evidence that it alone could cause CD
risk. Rather, CD risk was only present in haplotype and diplotype analyses when both
SLC22A4 and SLC22A5 functional alleles were found together and with the other minor
alleles in the extended, apparently European origin IBD5 haplotype compatible with the
finding from Fisher SA et al.38 Similar to the three established NOD2 risk mutations,
SLC22A4 Leu503Phe appears to originate completely from European admixture, not being
found in the Yoruban genome. One unifying hypothesis to explain risk in AA's restricted to
homozygotes vs. risk in whites only modestly increased in homozygotes relative to
heterozygotes, is that within persons of EA, there might exist multiple albeit less frequent,
additional SNPs besides Leu503Phe that similarly influence SLC22A4 epithelial transport
activity, and thus some Leu/Leu wild types may be heterozygotes for less common
SLC22A4 risk alleles, and some Leu/Phe heterozygotes may actually be compound
homozygotes. A recent evolutionary analysis is consistent with this hypothesis.39 Thus, the
true nature of IBD5 risk may be recessive for both white and AA populations. Interestingly,
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IBD5 risk for UC was found significant in meta-analysis only for recessive and not for
dominant inheritance.37
IL23R was the first gene identified by European GWAS and proven as a significant risk for
CD. We observed significant association in AA's with CD for intron7 IL23R SNP
(rs2201841) (p=0.03), but no significant association was observed for other SNPs including
the highly protective Arg381Gln variant – although power was limited given the 2.6%
381Gln allele frequency. In whites, rs2201841 has been shown as a risk factor independent
of Arg381, and thus association evidence for rs2201841 may be important.28 Our haplotype
analysis supported a role for IL23R in AA's showing nominal evidence for association for 2
of the 5 variant haplotypes with HC frequencies greater than 1% (Table 3). Given the
number of SNPs and haplotypes evaluated, larger studies are required to substantiate IL23R
as a risk for AA CD.
Although frequency of the ATG16L1 functional 300Ala variant is lower in AA's than
observed in our population-based study in Canadian whites (29% AA HC vs. 52% white
HC's), we observed similar and highly significant association (OR 1.41, p=0.003) with
CD.28 Given that 300Ala is relatively frequent in Yorubans (27.5%), unlike NOD2 and
SLC22A4 – in AA's the origin of the ATG16L1 functional variant risk is likely contributed
by both ancestral populations.
IRGM, which encodes a GTP-binding protein that induces autophagy and plays an important
role against intracellular pathogens, was recognized as CD risk gene by the Wellcome Trust
GWAS.16 A 20 kb promoter deletion in whites has been associated with reduced IRGM
expression in several cell types.16 We genotyped this 20 kb CNV in 96 AA's and observed
that similar to whites, the rs13361189 “c” allele was in perfect LD with the 20kb deletion
(data not shown), these minor alleles are nearly 20-fold more frequent in AA's relative to
whites. There is some controversy with regard to the influence of the 20 kb CNV: in a well-
powered Japanese study the CNV deletion polymorphism, although as in AA's also found at
relatively high frequency, also observed nearly identical presence among CD cases and
controls (37% and 38%, respectively).17 Hence, the background ancestry appears to have a
controlling influence on the 20kb CNV risk. However, our power to exclude risk was more
limited (51%-78% [Supplementary Table 6] vs. 90% in the Japanese study).17 Similarly,
neither our study nor the Japanese study observed risk for rs10065172, reported to influence
miRNA regulation of IRGM expression, and likewise found at high frequency in both
Japanese and AA's. One possible explanation for this observed lack of IRGM association
with CD in Japanese and AA is that, as proposed by Prescott et al., the true causal variant is
neither the CNV nor rs10065172, but arose on a haplotype in Europeans after the split with
African and Asian populations.17
AAs are a recently admixed population with an average of ～80% of African ancestry but
significant variation exists at individual level.40, 41 Studies of disease or phenotype patterns,
including obesity, skin pigmentation, psychiatric disorders, and asthma in AAs have shown
that African ancestry is different between cases and ethnicity matched controls from less
than 1% to 4%.5, 42-44 This study is the first large population-based study to investigate the
association between African ancestry and CD risk in AAs. Nonetheless, admixture was
essentially identical. This was despite the fact that NOD2 and IBD5 loci– both with greater
than 3-fold risks in our study - clearly arise only from European admixture. One explanation
may be the relatively low protection from CD – perhaps counterbalancing the NOD2 and
IBD5 risks – of IL23R 381Gln (present in only 5% of healthy AA's vs. 14% of healthy
whites). Other considerations include the possibility that there may exist high risk, African
ancestry variants yet to be discovered, and that our study had suboptimal power to identify
modest admixture differences below 3%. Admixture analysis did not identify any significant
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associations within CD sub-phenotypes and demographic features. Power was even more
limited for these analyses, however, and it will be of great interest to evaluate potential
admixture-phenotype expression features in a larger study population, especially for features
where a trend was observed, notably inflammatory vs. complicated disease behavior.
We previously provided the first evidence that family history of CD in AA's was
significant,4 suggesting that as in whites, AA CD would likely have genetic origins. In the
present study, we have provided strong evidence to support our previous modest evidence
that established NOD2 mutations contribute to CD risk in AA's, and provide evidence that
established functional polymorphisms in SLC22A4 and ATG16L1, and possibly an intronic
polymorphism in IL23R also contribute to AA CD risk. Unexpected findings of our study
include the nature of IBD5 risk as most likely recessive, the ability to isolate – likely from
the greater diversity of the African genome – the –g207c SLC22A5 risk allele and by
haplotype analysis provide evidence against it as a CD risk factor alone, and that the degree
of European admixture in CD and HC's would be so similar. This study represents an initial
characterization of CD genetic risk in AA's. This study shows that the established CD risk
genes in whites, NOD2, IBD5, and ATG16L1, also contribute to the risk of CD in AAs
without influence by their African ancestry. This finding could become increasingly more
critical with commercial laboratories now incorporating CD gene testing to predict disease
risk. Future studies evaluating additional established CD genes, with larger study
populations and more dense genotyping, as well as AA GWAS's to identify unique African
ancestral risk as well as protective variants are greatly anticipated to further elucidate the
nature of CD genetics in this under-investigated population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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MAAIS Multicenter African American IBD Study
IBDGC IBD Genetics Consortium
LD linkage disequilibrium
NOD2 Nucleotide-binding oligomerization domain containing-2
SLC22A4 Solute carrier family 22, member 4
SLC22A5 Solute carrier family 22, member 5
GWAS genome wide association study
IL23R interleukin (IL) 23 receptor
SNP single nucleotide polymorphism
ATG16L1 autophagy 16 like-1
IRGM immunity-related GTPase family, M
CNV copy number variation
IBD inflammatory bowel disease
GRC Genetics Research Center
AIM admixture informative marker
PAR population attributable risk
HWE Hardy-Weinberg Equilibrium
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Cumulative proportion of persons with increment of West African ancestry for (a) CD
(solid) vs. controls (dashed); (b)complicated (B2 or B3) (solid) vs. inflammatory behavior
(dashed); and (c) ileal (L1 or L3) (solid) vs. colon-only (L2) disease (dashed) sites. Linear
regression analyses treating WA as a continuous trait observed a borderline difference in
complicated vs. inflammatory behavior (p=0.07), and no differences in CD vs. controls
(p=0.57) or ileal vs. colon-only sites (p=0.55).
Wang et al. Page 16

























Wang et al. Page 17
Table 1
Baseline and clinical characteristics of cases (Crohn's disease) and controls (HC) in
primary dataset (MAAIS)
Characteristics CD (n=227) HC (n=200) P value*
Age at enrollment (years) 37.4 ± 14.3 39.8 ± 12.7 0.07
Age at diagnosis 26.7 ± 12.9 --
Gender (Male %) 34.2% 42.6% 0.08
Family history of IBD (%)§ 15.9% 0.0% <0.001
Cigarette smoking status: Never (%) 136 (65%) 91 (51.7%) 0.05
Former (%) 15 (7.1%) 20 (11.3%)
Current (%) 58 (27.9%) 65 (37%)
CD disease behavior B1:Inflammatory 92 (40.5%) -
B2: Stricture 67 (29.5%) -
B3: Penetrating (fistulizing) 52 (22.9%) -
Disease location L1: Ileal 49 (21.6%) -
L2: Colonic 70 (30.8 %) -
L3: ileocolonic 103 (45.3%) -
L4: isolated upper disease 2 (0.9%) -
Any Perianal Disease§ 70 (30.7%) -
Surgical Resection for CD§ 104 (46.0%) -
West African ancestry estimates (%) 0.796 +/- 0.116 0.798 +/- 0.119 0.86
§
Unknowns were 8 for family history, 13 for perianal, and 4 for surgery
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